Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Acupuncture shows promise in head and neck patients with xerostomia

Acupuncture significantly relieves the symptoms of xerostomia, or dry mouth, compared with oral care education in patients who have undergone radical or adjuvant radiotherapy for head and neck cancer, indicate the results of a randomized crossover trial.

1 Nov 2012

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, “Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials” to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.

30 Oct 2012

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

30 Oct 2012

Antidepressant doxepin eases pain associated with oral mucositis

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.

29 Oct 2012

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.

23 Oct 2012

HPV status predicts oropharyngeal cancer irradiation response

Human papillomavirus-positive head and neck cancer is more sensitive to the initial effects of radiation therapy than HPV-negative head and neck cancer, suggest study findings.

8 Oct 2012

F-18-FLT-PET predicts early response to chemoradiotherapy in head and neck cancer

Determining the optimal treatment course and predicting outcomes may get easier in the future for patients with head and neck sqaumous cell carcinomas (HNSCCs) with the use of an investigational imaging agent.

2 Oct 2012

Report illustrates safety and efficacy of transoral robotic surgery for supraglottic laryngectomy

Robotic surgery though the mouth is a safe and effective way to remove tumors of the throat and voice box, according to a study by head and neck cancer surgeons at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

27 Sep 2012

Henry Ford Hospital opens new Center for Cancer Surgery

With more patients seeking cancer treatment – especially surgery – than ever before, Henry Ford Hospital has opened the new Center for Cancer Surgery.

27 Sep 2012

The ABC of terminal hemorrhage management

To best cope with terminal hemorrhage, at-risk patients should be identified by healthcare professionals while their families and caregivers are prepared, supported, and instructed to assure, be there for, and calm and comfort the patient as the event occurs, say researchers.

26 Sep 2012

Regular Fanconi anemia cells aren't sensitive to resveratrol

Fanconi anemia is a recessive genetic disorder affecting 1 in 350,000 babies, which leaves cells unable to repair damaged DNA. This lack of repair puts Fanconi anemia patients at high risk for developing a variety of cancers, especially leukemias and head and neck cancer.

5 Sep 2012

CAD risk no higher in head and neck cancer

Researchers have shown that people with head or neck cancer are not necessarily at any greater risk for developing coronary artery disease than the general population.

4 Sep 2012

Sterotactic radiotherapy offers good results in recurrent head and neck cancer

For patients with recurring head and neck cancer, stereotactic body radiotherapy offers a feasible and tolerable salvage treatment, with median overall survival rates of more than 1 year, report researchers.

30 Aug 2012

Cancer patients with xerostomia can benefit from regenerative research

Biologists, surgical oncologists and regenerative medicine specialists from Rice University, the University of Delaware and the Christiana Care Health System in Wilmington, Del., have begun a four-year program aimed at using cells to grow whole salivary glands that can replace those destroyed by cancer radiation therapy.

16 Aug 2012

UD professor part of NIH-funded project to create artificial salivary glands

University of Delaware professor Xinqiao Jia is part of a research team breaking new ground in the creation of artificial salivary glands.

14 Aug 2012

Salvage surgery for oropharyngeal cancer needs due consideration

Japanese study results indicate a 5-year overall survival rate of 49% for oropharyngeal cancer patients treated with salvage surgery after initial treatment with chemoradiotherapy has failed.

9 Aug 2012

Study aims to raise awareness of nerve transfer surgery among health care providers

A study in the August issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) by Hospital for Special Surgery researchers aims to raise awareness of this type of surgery among health care providers.

1 Aug 2012

Treatment with robotic surgery offers dramatic benefit for people with head and neck cancer

Predictors of disease severity in human papillomavirus-derived head and neck cancer, tobacco use, and the dramatic benefits of robotic surgery in people with head and neck cancer are among landmark research presented by Mount Sinai School of Medicine at the Eighth International Conference on Head and Neck Cancer. The meeting took place from July 21-25, 2012 in Toronto.

27 Jul 2012

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.